BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15341483)

  • 1. Indolebutylamines as selective 5-HT(1A) agonists.
    Heinrich T; Böttcher H; Bartoszyk GD; Greiner HE; Seyfried CA; Van Amsterdam C
    J Med Chem; 2004 Sep; 47(19):4677-83. PubMed ID: 15341483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New 5-hydroxytryptamine(1A) receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation.
    Fiorino F; Perissutti E; Severino B; Santagada V; Cirillo D; Terracciano S; Massarelli P; Bruni G; Collavoli E; Renner C; Caliendo G
    J Med Chem; 2005 Aug; 48(17):5495-503. PubMed ID: 16107148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New 5-HT(1A) receptor ligands containing a N'-cyanoisonicotinamidine nucleus: synthesis and in vitro pharmacological evaluation.
    Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Santagada V; Caliendo G
    Bioorg Med Chem Lett; 2010 May; 20(9):2978-82. PubMed ID: 20347301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors.
    López-Rodríguez ML; Morcillo MJ; Fernández E; Benhamú B; Tejada I; Ayala D; Viso A; Campillo M; Pardo L; Delgado M; Manzanares J; Fuentes JA
    J Med Chem; 2005 Apr; 48(7):2548-58. PubMed ID: 15801844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
    Cussac D; Palmier C; Finana F; De Vries L; Tardif S; Léger C; Bernois S; Heusler P
    J Pharmacol Exp Ther; 2009 Oct; 331(1):222-33. PubMed ID: 19605522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity.
    Heinrich T; Böttcher H; Schiemann K; Hölzemann G; Schwarz M; Bartoszyk GD; van Amsterdam C; Greiner HE; Seyfried CA
    Bioorg Med Chem; 2004 Sep; 12(18):4843-52. PubMed ID: 15336263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT(1A) receptor.
    Perrone R; Berardi F; Colabufo NA; Lacivita E; Larizza C; Leopoldo M; Tortorella V
    J Pharm Pharmacol; 2005 Oct; 57(10):1319-27. PubMed ID: 16259761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of the 5-hydroxytryptamine (5-HT)1A receptor inverse agonists Rec 27/0224 and Rec 27/0074 on electrophysiological responses to 5-HT1A receptor activation in rat dorsal raphe nucleus and hippocampus in vitro.
    Corradetti R; Mlinar B; Falsini C; Pugliese AM; Cilia A; Destefani C; Testa R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):109-17. PubMed ID: 15951403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
    Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
    J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-intrinsic activity relationship studies in the group of 1-imido/amido substituted 4-(4-arylpiperazin-1-yl)cyclohexane derivatives; new, potent 5-HT1A receptor agents with anxiolytic- like activity.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Bugno R; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2006 Mar; 14(5):1391-402. PubMed ID: 16266808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
    J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5-HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives.
    Zhou D; Zhou P; Evrard DA; Meagher K; Webb M; Harrison BL; Huryn DM; Golembieski J; Hornby GA; Schechter LE; Smith DL; Andree TH; Mewshaw RE
    Bioorg Med Chem; 2008 Jul; 16(14):6707-23. PubMed ID: 18571421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
    Mewshaw RE; Zhou D; Zhou P; Shi X; Hornby G; Spangler T; Scerni R; Smith D; Schechter LE; Andree TH
    J Med Chem; 2004 Jul; 47(15):3823-42. PubMed ID: 15239661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.
    Kumar JS; Majo VJ; Hsiung SC; Millak MS; Liu KP; Tamir H; Prabhakaran J; Simpson NR; Van Heertum RL; Mann JJ; Parsey RV
    J Med Chem; 2006 Jan; 49(1):125-34. PubMed ID: 16392798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
    J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
    Heinrich T; Böttcher H; Gericke R; Bartoszyk GD; Anzali S; Seyfried CA; Greiner HE; Van Amsterdam C
    J Med Chem; 2004 Sep; 47(19):4684-92. PubMed ID: 15341484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New 4-[omega-(diarylmethylamino)alkyl]- and 4-[omega-(diarylmethoxy)alkyl]-1-arylpiperazines as selective 5-HT1A/5-HT2A receptor ligands with differentiated in vivo activity.
    Paluchowska MH; Charakchieva-Minol S; Tatarczyńska E; Kłodzińska A; Stachowicz K; Chojnacka-Wójcik E
    Pol J Pharmacol; 2004; 56(6):743-54. PubMed ID: 15662087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
    Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
    J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.